Click Here to learn about our most recent updates, visitor restrictions, testing, safety precautions and more.

What can we help you find?

Sorry, we couldn't find any content for "{{results_term}}." Try searching again.

COVID-19 Resources

Clinical Trials for COVID-19

As Cincinnati’s academic health system, it is our privilege and our responsibility to be a source of hope for those who need it most. One way we offer hope is through our tireless commitment to research.

As the leaders in research, teaching and clinical care in Greater Cincinnati, the University of Cincinnati, UC Health, Cincinnati Children’s Hospital Medical Center and Cincinnati Department of Veterans Affairs Medical Center are working together in scientific discovery to help treat, prevent and cure COVID-19.

Right now, our researchers are:

  • Learning more about the virus, including transmission, and how it affects people with specific conditions.
  • Studying possible treatment options.
  • Studying why some people get sicker than others.
  • Identifying how many people are infected.
  • Determining how our immune systems will protect us from future infections.


COVID-19 Vaccine Study

The goal of UC Health and the University of Cincinnati is to host multiple clinical trials designed to evaluate the safety and effectiveness of COVID-19 vaccines.

If you are interested in being contacted in the future about a COVID-19 vaccine trial, please complete this brief survey. Study teams will be reaching out to eligible participants with more information during the enrollment process.


Convalescent Plasma

On March 24, 2020, the U.S. Food and Drug Administration (FDA) began allowing researchers to request emergency authorization for the use of convalescent plasma, which shows potential as a treatment for COVID-19. We are following a research protocol from the Mayo Clinic to take “convalescent plasma,” or plasma obtained from those who have recovered from COVID-19, and administer it to hospitalized patients infected with the novel coronavirus who have severe or life-threatening symptoms, or who may be at high risk for progression to severe or life-threatening disease.

As part of the Mayo Clinic protocol, UC and UC Health will be working with Cincinnati’s Hoxworth Blood Center to obtain the convalescent plasma from eligible donors. Hoxworth Center is seeking individuals who:

  • Have recovered from a documented infection of COVID-19 and have been symptom-free for at least 28 days.

  • Believe they had COVID-19. The product will be tested for antibodies following donation. If your plasma does not contain high levels of antibodies to COVID-19, it may be used to help save the lives of other patients.

If you tested positive for COVID-19, or believe you had COVID-19, and have been fully recovered for at least 28 days, please click here to fill out the eligibility form and get scheduled for a donation today. Appointments are required for donation.



IRB# 2020-0437
This study is for patients who are at high risk of developing COVID-19 after being exposed to someone who is infected with the novel coronavirus. The study will determine whether giving these patients plasma with antibodies will prevent illness or lessen the severity of the illness. This plasma comes from people who have recovered from COVID-19. Researchers will study two groups of people: one group will receive antibodies with plasma and the other will receive regular plasma.

Study contacts



The study will determine whether giving plasma with antibodies to people infected with the novel coronavirus will prevent illness or lessen the severity of the illness. This plasma comes from people who have recovered from COVID-19. Researchers will study two groups of people: one group will receive antibodies with plasma and the other will receive regular plasma.

Study contacts


DAS181 Study

IRB# 2020-0367
The DAS181 trial is designed using a new antiviral therapy intended to attack the virus. This experimental treatment is offered through a nebulizer treatment and sponsored by Ansun Biopharmaceuticals. The new treatment will test whether we can limit and decrease the amount of infection in someone with COVID-19 pneumonia. Study participation will be offered to both adults and children (through our partners at Cincinnati Children’s Hospital). Researchers hope to enroll 82 people in the study nationally to determine the safety and effectiveness of this treatment.

Study contact



IRB# 2020-0337
The SCOPE trial examines the drug sirolimus, an FDA approved treatment for patients with a rare lung disease called LAM, which can improve the clinical outcomes of patients hospitalized for COVID-19. Researchers believe it can help regulate the immune response to the virus. This is an investigator-initiated trial and is only being offered at UC.

Study contacts


CCR Study

IRB# 2020-0329
The CCR trial is a COVID-19 observational study with sample and data collection to provide a mechanism to collect medical record data and specimens (peripheral blood, sputum, nasal swab, oropharyngeal swab, stool, mini bronchoalveolar lavage (BAL), remnant BAL and tissue specimens including post-mortem biopsies) that will provide insights into the pathophysiology of a novel infectious agent, and aid in the development of new diagnostic tools and treatment strategies for patients with COVID-19.

Study contacts



IRB# 2020-0409
This study will determine the effectiveness and safety of the drug ruxolitinib in patients with acute respiratory distress syndrome (ARDS) associated with COVID-19 who need a ventilator.

Study contacts



IRB# 2020-0427
This trial is a study of an oral antiviral medication called AT-527 in older patients (ages 45–80 years) with moderate COVID-19 who also have risk factors for poor outcomes, such as obesity, hypertension, diabetes or asthma. The objectives of this study are to determine the drug’s effectiveness, safety and negative effects in this patient population. Subjects will receive either the drug or placebo by mouth for 10 days.

Study contacts



IRB# 2020-0349
This inpatient trial will study whether a medication called Losartan will help improve breathing problems in people who are recovering from COVID-19. Losartan is designed to block a hormone that damages lung tissue. In a healthy person, a kind of protein helps protect the lungs from this damaging hormone. However, COVID-19 blocks this protective protein.

Study contact


By encouraging participation in our clinical trials, we can help find treatments, cures, and prevention opportunities that could possibly save lives. If you or someone you know has COVID-19 or has recovered from COVID-19 and would be interested in learning more about available trials, please contact or call 513-245-3417.

Our researchers, like our clinicians and staff, have been the embodiment of “In science lives hope” during this pandemic.  We are all working hard to offer hope to our patients, their families, and our communities during this unprecedented time.